011040.KQ Kyung Dong Pharmaceutical Co. Ltd
- Market cap
- KRW 142B
- P/E
- -
- P/B
- 0.61x
- ROE
- 9.1%
- Dividend yield
- 5.69%
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 011040.KQ undervalued?
Graham numberThe Graham number of Kyung Dong Pharmaceutical Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kyung Dong Pharmaceutical Co. Ltd fundamental analysis
11 of 22 checks passedROE 0/2
Low return on equity (9.1%), below 10%.
ROA 1/1
Return on assets (6.8%) is above the industry median (3.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (43.4%) is above the 5-year average (-8.3% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (43.4%) is above the industry median (6.6%).
Revenue Growth 1/2
Revenue grew 2.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (6.7%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 16.1x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.6x) is below the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (5.7%) is in the top 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
Payout ratio is 94.8%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Kyung Dong Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kyung Dong Pharmaceutical Co. Ltd
Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, antihistamine, CNS, antiobesity, neuropathic, osteoporosis, respiratory, allergy, a…
Full company profileKyung Dong Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kyung Dong Pharmaceutical Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 159B | 178B | 179B | 177B | 174B | 178B | 183B | 163B | 194B | 196B | 200B |
| Gross Profit | 93.9B | 102B | 105B | 104B | 98.6B | 97.2B | 95.0B | 88.3B | 114B | 117B | 124B |
| Operating Income | 24.1B | 30.8B | 20.2B | 37.3B | 19.0B | 15.8B | 7.81B | -24.7B | 2.51B | 7.67B | 12.2B |
| EBITDA | - | - | - | - | - | - | 25.5B | -11.1B | 12.8B | 14.6B | 31.4B |
| Net Income | 17.6B | 20.5B | 5.24B | 20.1B | 12.5B | 12.7B | 12.2B | -20.7B | 5.47B | 8.53B | 21.1B |
| EPS | 749 | 868 | 221 | 850 | 450 | 465 | 448 | -763 | 203 | 291 | 719 |
| Balance Sheet | |||||||||||
| Total Assets | 238B | 251B | 258B | 288B | 291B | 292B | 310B | 293B | 303B | 322B | 308B |
| Total Liabilities | 28.6B | 30.5B | 46.1B | 60.9B | 29.2B | 32.2B | 53.3B | 64.5B | 82.8B | 93.0B | 76.3B |
| Shareholders' Equity | 210B | 221B | 212B | 227B | 262B | 260B | 257B | 228B | 220B | 228B | 231B |
| Cash & Short-term Investments | 64.5B | 53.1B | 83.9B | 95.0B | 61.3B | 50.0B | 45.1B | 32.1B | 30.9B | 31.8B | 13.1B |
| Total Debt | - | - | - | 25.9B | 1.06B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 25.6B | 14.8B | 33.3B | -2.78B | 17.1B | 12.4B | -1.07B | -31.9M | -8.07B | 16.9B | 20.9B |
| Capital Expenditure | 7.19B | 5.74B | 3.93B | 2.05B | 28.6B | 3.93B | 11.7B | 8.49B | 11.8B | 20.5B | 5.37B |
| Free Cash Flow | - | - | - | - | -11.8B | 7.69B | -12.8B | -8.53B | -19.8B | -3.58B | 15.5B |
| Ratios | |||||||||||
| ROE | 8.4% | 9.3% | 2.5% | 8.9% | 4.8% | 4.9% | 4.7% | -9.1% | 2.5% | 3.7% | 9.1% |
| ROA | 7.4% | 8.1% | 2.0% | 7.0% | 4.3% | 4.3% | 3.9% | -7.1% | 1.8% | 2.6% | 6.8% |
| Net Profit Margin | 11.1% | 11.5% | 2.9% | 11.4% | 7.2% | 7.1% | 6.7% | -12.7% | 2.8% | 4.3% | 10.5% |
| Debt to Equity | - | - | - | 0.11x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kyung Dong Pharmaceutical Co. Ltd dividends
- Dividend yield
- 5.69%
- Forward dividend
- -
- Payout ratio
- 94.8%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 8.08B | 276 | 94.8% |
| 2024 | KRW 10.9B | 403 | 198.4% |
| 2023 | KRW 10.9B | 400 | - |
| 2022 | KRW 10.9B | 401 | 89.6% |
| 2021 | KRW 13.8B | 508 | 109.2% |
| 2020 | KRW 11.8B | 427 | 94.9% |
| 2019 | KRW 7.10B | 300 | 35.3% |
| 2018 | KRW 9.43B | 398 | 179.9% |
| 2017 | KRW 8.23B | 349 | 40.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on May 15, 2018.
Who owns Kyung Dong Pharmaceutical Co. Ltd
- Insiders 44.58%
- Institutions 0.81%
- Public & others 54.61%
- Shares outstanding 23.5M
- Free float 13.4M
Kyung Dong Pharmaceutical Co. Ltd company profile
- Company name
- Kyung Dong Pharmaceutical Co. Ltd
- Ticker
- 011040.KQ
- ISIN
- KR7011040003
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 589
- Fiscal year end
- December
- Address
- KyongDong Pharmaceutical Building, Seoul, South Korea
- Phone
- 82 2 576 6121
- Website
- kdpharma.co.kr
About Kyung Dong Pharmaceutical Co. Ltd
Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, antihistamine, CNS, antiobesity, neuropathic, osteoporosis, respiratory, allergy, and arthrifuge categories. The company also provides OTC medicines for pain/inflammation, cardiovascular, hepatic protectors, respiratory, gastrointestinal, calcium agent, antihistamine, antifungal, antibiotic, anti-inflammatory enzyme, dermatologic, antiviral, and contraceptive categories; and APIs and health functional foods, as well as quasi drugs. The company was formerly known as Yuil Trading Company and changed its name to Kyung Dong Pharmaceutical Co., Ltd. in February 1976. Kyung Dong Pharmaceutical Co., Ltd. was founded in 1975 and is headquartered in Seoul, South Korea.
Kyung Dong Pharmaceutical Co. Ltd management
8- Deok-Hee RyuChairman, Chief Exec. Officer and Pres · born 1938
- Byung-Seok LeeChief Exec. Officer and Pres · born 1953
- Gi-Sung RyuChief Exec. Officer and VP · born 1982
- Mr. Gi-Cheol NamSr. Managing Director · born 1957
- Won-Kyo ParkManaging Director · born 1962
- Byung-Jo ParkManaging Director · born 1960
- Hyung-Jun GilManaging Director · born 1959
- Yoon-Sub ShinManaging Director · born 1959